Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;84(4):1098-1100.
doi: 10.1016/j.jaad.2020.12.043. Epub 2020 Dec 24.

Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study

Hamidreza Mahmoudi  1 , Ali Salehi Farid  1 , Ali Nili  1 , Dorsa Dayani  1 , Soheil Tavakolpour  2 , Tahereh Soori  1 , Amir Teimourpour  1 , Ahdie Isazade  1 , Robabeh Abedini  1 , Kamran Balighi  1 , Maryam Daneshpazhooh  3 ; Autoimmune Bullous Diseases Research Group
Affiliations

Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study

Hamidreza Mahmoudi et al. J Am Acad Dermatol. 2021 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest None disclosed.

Figures

Fig 1
Fig 1
Univariate and multivariate analysis with IPW. Association between prednisolone and rituximab infusion with COVID-19 in patients with autoimmune bullous diseases. Asterisk indicates all 704 patients were included in the total COVID-19 analysis. For the diagnosed COVID-19 analysis, highly suspicious cases were excluded from the cohort. Likewise, both highly suspicious and nonhospitalized COVID-19 cases were excluded from the cohort in the hospitalized COVID-19 analysis. Double asterisk indicates outcomes: Total COVID-19 including diagnosed and highly suspicious cases; diagnosed COVID-19 cases; hospitalized COVID-19 cases. Hashtag indicates RTX interval was analyzed for patients who received RTX after April 2019 and was defined as the interval from the last dose of RTX to either the date of contracting COVID-19 or May 2020. The blue line shows the relative risk of outcomes with each passing month from the last RTX infusion with a 95% CI.
See this image and copyright information in PMC

References

    1. Kasperkiewicz M., Schmidt E., Fairley J., et al. Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2020 - PMC - PubMed
    1. Organization W.H. World Health Organization; 2020. Use of chest imaging in COVID-19: a rapid advice guide, 11 June 2020.
    1. Gianfrancesco M., Hyrich K.L., Al-Adely S., et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. - PMC - PubMed
    1. RECOVERY Collaborative Group. Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. Published online July 17, 2020 doi: 10.1056/NEJMoa2021436. - DOI
    1. Guilpain P., Le Bihan C., Foulongne V., et al. Response to: ‘Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab’ by Avouac et al. Ann Rheum Dis. 2020 - PubMed

Publication types